Literature DB >> 6926749

Synthesis of (-)-15-deoxyspergualin and (-)-spergualin-15-phosphate.

H Iwasawa, S Kondo, D Ikeda, T Takeuchi, H Umezawa.   

Abstract

The method for chemical modification of spergualin with retention of the configuration at the C-11 has been achieved by the use of tetrahydropyranyl group for protection of the 11-hydroxyl group. (-)-15-Deoxyspergualin (2), which shows about eight times stronger inhibition against mouse leukemia L-1210 than the natural (-)-spergualin(1), and (-)-spergualin-15-phosphate(3) possessing a good antitumor activity have been synthesized starting from 1.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6926749     DOI: 10.7164/antibiotics.35.1665

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  8 in total

1.  Mechanism of action of 15-deoxyspergualin. I. Suppressive effect on the induction of alloreactive secondary cytotoxic T lymphocytes in vivo and in vitro.

Authors:  K Nishimura; T Tokunaga
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

2.  Suppression of host resistance against Listeria monocytogenes infection by 15-deoxyspergualin in mice.

Authors:  A Nakane; A Numata; T Minagawa
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

3.  Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias.

Authors:  Patrick Ziegler; Tuhama Chahoud; Thomas Wilhelm; Nora Pällman; Melanie Braig; Valeska Wiehle; Susanne Ziegler; Marcus Schröder; Chris Meier; Adrian Kolodzik; Matthias Rarey; Jens Panse; Joachim Hauber; Stefan Balabanov; Tim H Brümmendorf
Journal:  Invest New Drugs       Date:  2012-03-14       Impact factor: 3.850

4.  Prolongation of graft survival in allogeneic islet transplantation by (-) 15-deoxyspergualin in the rat.

Authors:  P K Walter; G Dickneite; H U Schorlemmer; H H Sedlacek; S Jäger; G Feifel; G Seitz
Journal:  Diabetologia       Date:  1987-01       Impact factor: 10.122

5.  15-Deoxyspergualin (15-DOS) has a curative effect on the development of SLE-like autoimmune disease in MRL/1 mice.

Authors:  H U Schorlemmer; R R Bartlett; F R Seiler
Journal:  Agents Actions       Date:  1991-09

6.  Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo.

Authors:  S D Harrison; R W Brockman; M W Trader; W R Laster; D P Griswold
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

7.  Suppression of pulmonary injury in experimental 'Goodpasture's syndrome' by deoxyspergualin (DSP).

Authors:  H Y Lan; D J Nikolic-Paterson; M Zarama; P G Kerr; R C Atkins
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

8.  Phase I study of NKT-01.

Authors:  K Tamura; H Niitani; M Oguro; R Ohno; K Sanpi; H Majima; T Masaoka; I Kimura; J Inagaki; Y Suzuoki
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.